AbbVie Files US, Europe Applications For Skyrizi In Psoriatic Arthritis

AbbVie Inc ABBV has submitted marketing applications to the FDA and European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab-rzaa, 150 mg) for the treatment of adults with active psoriatic arthritis.
In the Phase 3 KEEPsAKE-1 and KEEPsAKE-2 studies, Skyrizi demonstrated significant improvements in disease activity, skin clearance, and physical function at week 24 versus placebo.
Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
Price Action: ABBV shares were down 0.28% at $105.09 during market trading hours on the last check Wednesday.

Momentum79.84

Growth40.12

Quality30.21

Value13.17

Short

Medium

Long